News Lumosa Therapeutics Co., Ltd.

Equities

6535

TW0006535008

End-of-day quote Taipei Exchange Other stock markets 23:00:00 14/05/2024 BST			5-day change	1st Jan Change
183.5 ^TWD	-7.56%		-2.65%	+168.67%

05-14	Lumosa Therapeutics Co., Ltd. Announces the Change of Chairperson	CI
05-14	Lumosa Therapeutics Co., Ltd. Announces the Change in Juristic-Person Director Representative	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lumosa Therapeutics Co., Ltd. Announces the Change of Chairperson	05-14	CI
Lumosa Therapeutics Co., Ltd. Announces the Change in Juristic-Person Director Representative	05-14	CI
Lumosa Therapeutics Co., Ltd. announced that it expects to receive TWD 50 million in funding	05-13	CI
Lumosa Therapeutics Co., Ltd. cancelled the transaction announced on May 31, 2023	04-23	CI
GenEditBio Limited announced that it has received funding from Lumosa Therapeutics Co., Ltd., Qiming Weichuang Venture Capital Management Company Limited, Innovation & Technology Fund Company, Hong Kong Science and Technology Parks, Investment Arm	04-06	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Lumosa Therapeutics and CHI Memorial Announce New Study for Acute Stroke	02-02	CI
Lumosa Therapeutics Co., Ltd. Receives Approval to Initiate Phase 2, Multiple-Dose Study of Its LT3001	01-22	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
Lumosa Therapeutics Co., Ltd. Approves the Exclusive Licensing Agreement with Gufic Biosciences for LT1001, A Long-Acting Analgesic Injection	11-09	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
Lumosa Therapeutics Co., Ltd. Approves Formulation Patent for Lumosas Lt3001, A New Drug for Acute Ischemic Stroke	26/07/23	CI
Lumosa Therapeutics Co., Ltd. Appoints Hsin-Jung Lin as Member of the Audit Committee	31/05/23	CI
Lumosa Therapeutics Co., Ltd. Announces Appointment of Hsin-Jung Lin as Independent Director	31/05/23	CI
Lumosa Therapeutics Co., Ltd. announced a financing transaction	30/05/23	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Lumosa Therapeutics Co., Ltd. Appoints Lanying Huang as Corporate Governance Officer	12/05/23	CI
Lumosa Therapeutics Co., Ltd. announced a financing transaction	09/03/23	CI
Lumosa Therapeutics Co., Ltd. Approves Exclusive Licensing Agreement with Pakistan’s AJM Pharma Pvt. Ltd. for LT1001, A Long-Acting Analgesic Injection	23/12/22	CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Lumosa Therapeutics Co., Ltd.

Equities

6535

TW0006535008

Summary

Filters